| pubmed-article:7655872 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7655872 | lifeskim:mentions | umls-concept:C0018099 | lld:lifeskim |
| pubmed-article:7655872 | lifeskim:mentions | umls-concept:C0376387 | lld:lifeskim |
| pubmed-article:7655872 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7655872 | lifeskim:mentions | umls-concept:C0018823 | lld:lifeskim |
| pubmed-article:7655872 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:7655872 | lifeskim:mentions | umls-concept:C0868928 | lld:lifeskim |
| pubmed-article:7655872 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:7655872 | pubmed:dateCreated | 1995-10-5 | lld:pubmed |
| pubmed-article:7655872 | pubmed:abstractText | Gout in heart transplant recipients is common and poses a significant therapeutic challenge. Concomitant administration of azathioprine and allopurinol therapy carries a high risk of leukopenia. Uricosuric agents can cause renal lithiasis and/or acute renal failure in patients with renal failure and/or high urinary levels of uric acid. We report our experience with urate-oxidase in three heart transplant recipients with severe polyarticular and tophaceous gout, a history of leukopenia under allopurinol and unresponsiveness or contraindications to uricosuric agents. Urate-oxidase was given parenterally in a dosage of 1000 units per day, seven days a month. The injections were done intramuscularly in one patient and intravenously in the other two, who were under anticoagulant therapy. Patients 1 and 2 received 12 and 6 courses, respectively. The third patient had had four courses and was still under treatment at the time of this writing. Shrinking of the tophi and improved mobility of the fingers were seen in all three patients after the second course. No adverse effects were recorded. Our experience suggests that urate-oxidase therapy may decrease the urate burden in patients with severe tophaceous gout. Urate-oxidase therapy should be viewed as a phase in the treatment of gout, which must be followed by administration of another agent. | lld:pubmed |
| pubmed-article:7655872 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7655872 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7655872 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7655872 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7655872 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7655872 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7655872 | pubmed:month | May | lld:pubmed |
| pubmed-article:7655872 | pubmed:issn | 1169-8446 | lld:pubmed |
| pubmed-article:7655872 | pubmed:author | pubmed-author:BourgeoisPP | lld:pubmed |
| pubmed-article:7655872 | pubmed:author | pubmed-author:RocheBB | lld:pubmed |
| pubmed-article:7655872 | pubmed:author | pubmed-author:KoegerA CAC | lld:pubmed |
| pubmed-article:7655872 | pubmed:author | pubmed-author:RozenbergSS | lld:pubmed |
| pubmed-article:7655872 | pubmed:author | pubmed-author:DorentRR | lld:pubmed |
| pubmed-article:7655872 | pubmed:author | pubmed-author:BorgetCC | lld:pubmed |
| pubmed-article:7655872 | pubmed:author | pubmed-author:WrongDD | lld:pubmed |
| pubmed-article:7655872 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7655872 | pubmed:volume | 62 | lld:pubmed |
| pubmed-article:7655872 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7655872 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7655872 | pubmed:pagination | 392-4 | lld:pubmed |
| pubmed-article:7655872 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:7655872 | pubmed:meshHeading | pubmed-meshheading:7655872-... | lld:pubmed |
| pubmed-article:7655872 | pubmed:meshHeading | pubmed-meshheading:7655872-... | lld:pubmed |
| pubmed-article:7655872 | pubmed:meshHeading | pubmed-meshheading:7655872-... | lld:pubmed |
| pubmed-article:7655872 | pubmed:meshHeading | pubmed-meshheading:7655872-... | lld:pubmed |
| pubmed-article:7655872 | pubmed:meshHeading | pubmed-meshheading:7655872-... | lld:pubmed |
| pubmed-article:7655872 | pubmed:meshHeading | pubmed-meshheading:7655872-... | lld:pubmed |
| pubmed-article:7655872 | pubmed:meshHeading | pubmed-meshheading:7655872-... | lld:pubmed |
| pubmed-article:7655872 | pubmed:meshHeading | pubmed-meshheading:7655872-... | lld:pubmed |
| pubmed-article:7655872 | pubmed:meshHeading | pubmed-meshheading:7655872-... | lld:pubmed |
| pubmed-article:7655872 | pubmed:meshHeading | pubmed-meshheading:7655872-... | lld:pubmed |
| pubmed-article:7655872 | pubmed:meshHeading | pubmed-meshheading:7655872-... | lld:pubmed |
| pubmed-article:7655872 | pubmed:meshHeading | pubmed-meshheading:7655872-... | lld:pubmed |
| pubmed-article:7655872 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7655872 | pubmed:articleTitle | Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. | lld:pubmed |
| pubmed-article:7655872 | pubmed:affiliation | Department of Rheumatology, Pitié-Salpétrière Teaching Hospital, Paris, France. | lld:pubmed |
| pubmed-article:7655872 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7655872 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7655872 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7655872 | lld:pubmed |
